FWBI 81X Upside Potential according to this Analyst!

On 5/26/2022 Roth Capital brokerage Lowered the Price Target for First Wave BioPharma, Inc. (FWBI) from $600.00 to $270.00 giving a Buy Rating for the stock!

The stock is now at a historic low: $3.31.
In January 2021 it was $788.

Just to reach the Analyst Price Target, it need to grow 81.5X from this level.
The Market cap is extremely low: 4.58 Mil. 81X would be $371 Mil.
And wouldn`t be too much, if we look at their pipeline: 2 candidates reaching Phase 3 clinical trials, 3 candidates in Phase 2 and one in Phase one, in the following fields: Digestive/Nutritional Diseases, Inflammatory Diseases and Oncology.
It can explode anytime.

Even though the institutional ownership it`s not high, some of the shareholders that recently reported increasing stakes in the company are: Goldman Sachs, Blackrock and Jane Street Group.

This one is a premium call in my opinion.
Looking forward to read your opinion about it.